Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma

Figure 1

Metformin and tamoxifen inhibit the viability of MCF-7 and ZR-75-1 cells. (A-B) MCF-7 and ZR-75-1 cells were treated with tamoxifen at different concentrations (0, 0.25, 0.5, 1, 2, 4, 8, 16, 32 and 64 μM). After 2 or 4 days, the cell viability was measured. (C-D) MCF-7 and ZR-75-1 cells were treated with metformin at different concentrations (0, 0.625, 1.25, 2.5, 5, 10, 20, 40, 80 and 160 mM). After 2 or 4 days, the cell viability was measured. (E-F) MCF-7 and ZR-75-1 cells were treated with 5 or 10 μM tamoxifen, 5 mM metformin, or a combination of the two agents for 4 days, and the cell viability was measured. Histograms represent quantification of cell viability. All data are expressed as the mean ± standard deviation (SD) from three independent experiments. *P < 0.05 for the 5 μM Tam group vs. the 5 μM Tam + 5 mM Met group; # P < 0.05 for the 10 μM Tam group vs. the 10 μM Tam + 5 mM Met group. Tam and Met represent tamoxifen and metformin, respectively.

Back to article page